Press coverage about Zosano Pharma Corporation (NASDAQ:ZSAN) has been trending somewhat positive recently, according to Accern Sentiment. The research firm scores the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Zosano Pharma Corporation earned a daily sentiment score of 0.13 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 46.3026640393657 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the news articles that may have impacted Accern Sentiment Analysis’s rankings:
- Comparing KemPharm (KMPH) & Zosano Pharma Corporation (ZSAN) (americanbankingnews.com)
- Zosano Pharma Reports Third Quarter 2017 Financial Results and Operational Update (finance.yahoo.com)
- Zosano Pharma Corporation (ZSAN) Announces Quarterly Earnings Results (americanbankingnews.com)
- Zosano Pharma (ZSAN) Initiates Long-Term Safety Study for M207 as Acute Treatment of Migraine (streetinsider.com)
- Zosano Pharma Announces Initiation of Long-Term Safety Study for M207 as an Acute Treatment of Migraine (finance.yahoo.com)
Separately, ValuEngine raised Zosano Pharma Corporation from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st.
Shares of Zosano Pharma Corporation (ZSAN) traded down $0.01 during midday trading on Tuesday, hitting $0.68. The stock had a trading volume of 393,200 shares, compared to its average volume of 1,570,178. Zosano Pharma Corporation has a twelve month low of $0.54 and a twelve month high of $3.54.
Zosano Pharma Corporation (NASDAQ:ZSAN) last announced its earnings results on Thursday, November 9th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.15) by ($0.05). research analysts predict that Zosano Pharma Corporation will post -0.79 EPS for the current year.
About Zosano Pharma Corporation
Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability.
Receive News & Ratings for Zosano Pharma Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma Corporation and related companies with MarketBeat.com's FREE daily email newsletter.